Biomarkers are the critical missing links in the search for better Parkinson’s disease treatments.
The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate people with Parkinson’s disease and those at greater risk of developing the disease, as well as healthy controls. The goal is to identify one or more biomarkers of Parkinson’s disease progression. This longitudinal study, following over 1,000 participants for up to 8 years, is taking place at 33 clinical sites in the United States, Europe, Israel and Australia.
Critical data and biospecimens are currently available for the research community.
The comprehensive PPMI database and biorepository, includes:
> Clinical and behavioral assessments
> Imaging data
> Biospecimens: cerebral spinal fluid, DNA, RNA, plasma, serum, urine and cell lines
Use the database effectively.
The PPMI Statistics Core at the University of Iowa provides invaluable information about the PPMI database during this 13 minute webinar.
PPMI is made possible by the concerted efforts of a number of collaborators and sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Parkinson’s UK and the Critical Path Institute (C-Path) in Tucson, Arizona, recently launched the Critical Path for Parkinson’s consortium (CPP) to create a quantitative model of Parkinson’s progression from its earliest stages that will allow researchers to optimize clinical trial design for faster and more effective testing of new therapies. To achieve this goal, C-Path […]
The Parkinson’s Progression Markers Initiative (PPMI) announced the availability of induced pluripotent stem cells (iPSCs) for research to speed new therapies and deeper understanding of Parkinson’s disease. iPSCs are “man-made” stem cells created by taking a person’s own skin or blood cells and reprogramming them. These stem cells can then be made into other types […]
Vera Kiyasova, PhD, Clinical Development Leader at Servier, is the current chair of the PPMI Industry & Scientific Advisory Board (ISAB). She spoke to us about the importance of both PPMI and industry’s involvement with the study.
Chelsea Caspell-Garcia and Eric Foster from the PPMI Statistics Core at the University of Iowa provide invaluable information about the PPMI database during this 13 minute webinar.
In late spring, investigators from the Parkinson’s Progression Markers Initiative (PPMI) gathered in New York City for their annual meeting. Also in attendance were a handful of PPMI participants who are members of the PPMI Patient Committee. These research volunteers penned a letter to the PPMI community sharing their gratitude to the many people involved […]